Menin and DOT1L are critical cofactors in MLL-rearranged (MLL-r) leukemias, where their combined inhibition acts synergistically to trigger leukemia cell differentiation and apoptosis by disrupting the MLL-fusion protein complex on chromatin. Menin inhibitors (revumenib) block Menin-KMT2A binding, while DOT1L inhibitors (pinometostat) target the H3K79 methyltransferase, both suppressing key target genes like HOXA9 and MEIS1.
..
Glutathione S-Transferase
Function: Primarily, GSTs catalyze the conjugation of glutathione (GSH) to harmful, electrophilic substances, rendering them more water-soluble and easier to excrete.
Significance: They function in detoxification, signaling, and protecting cells against oxidative stress-induced cell death.
Structure: They often exist as dimers and are present in almost all aerobic organisms, including plants, where they are crucial for stress response.
Clinical Relevance: Genetic polymorphisms in human GSTs can alter susceptibility to cancer and inflammatory diseases. They are also associated with drug resistance in parasites.
4-Phenylbutyrate (4-PBA) is an FDA-approved chemical chaperone that acts as a potent inhibitor of endoplasmic reticulum (ER) stress, a cellular state linked to neurodegeneration and metabolic diseases. By promoting proper protein folding, 4-PBA reduces protein aggregation, directly counteracting the need for, or assisting in, ER-phagy (selective autophagy of the ER) to manage misfolded proteins.
Key Aspects of 4-PBA in ER Stress Management:
Mechanism of Action: As a chemical chaperone, 4-PBA interacts with exposed hydrophobic segments of unfolded proteins, preventing their aggregation and facilitating correct folding.
ER Stress Reduction: It effectively reduces the accumulation of misfolded proteins in the ER, thereby limiting ER stress-induced apoptosis.
Therapeutic Applications: 4-PBA is utilized to treat urea cycle disorders and has shown promise in treating neurodegenerative diseases (Parkinson’s, Alzheimer's), as well as non-alcoholic fatty liver disease, chronic kidney disease, and ocular HSV-1.
Relationship to ER-phagy: While ER-phagy is a mechanism for removing damaged ER, 4-PBA serves as a protective, upstream agent that reduces the severity of stress, often decreasing the need for massive ER degradation.
4-PBA functions broadly to maintain cellular homeostasis and reduce the pathological impact of ER dysfunction.
Key 4-PBA Derivatives and Related Compounds
C5 (isopropyl 4-PBA): A modified derivative designed to cross the blood-brain barrier.
3-Phenylpropionate (3-PPA): A related short-chain fatty acid tested for chaperone activity.
5-Phenylvaleric acid: A longer-chain derivative studied for ER stress reduction.
6-Phenylhexanoic acid: A further lengthened derivative tested for protein aggregation inhibition
4-Phenylbutyric acid (4-PBA) is a multifunctional small molecule acting as a chemical chaperone to alleviate endoplasmic reticulum (ER) stress, an HDAC inhibitor (HDACi), and an ammonia scavenger used for urea cycle disorders. It stabilizes protein conformation, reduces misfolding, and has potential in treating neurodegenerative and metabolic diseases.
Key Derivatives and Related Compounds:
4-Phenylbutyramide: A derivative often investigated for increased metabolic stability and potency as a chaperone.
3-Phenylpropionic acid (3-PPA): A structurally related, shorter-chain analogue with similar, albeit usually weaker, chemical chaperone properties.
Phenylacetate: The direct metabolite of 4-PBA, which also acts as an ammonia scavenger.
4-phenylbutyrate derivatives: Various synthetic derivatives have been developed to enhance the ability of 4-PBA to prevent protein misfolding, particularly for conditions like ALS.
Key Functions
Chemical Chaperone: Interacts with hydrophobic segments of unfolded proteins to prevent aggregation and reduce ER stress.
HDAC Inhibitor (HDACi): Increases histone acetylation to modulate gene expression, often inhibiting cancer cell proliferation.
Ammonia Scavenger: Metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, which is then excreted in urine, bypassing the urea cycle.
4-PBA is also known for reducing lipotoxicity in hepatoma cells and protecting against cardiac ischemia-reperfusion injury.
Phenylacetic acid (PAA) and its derivative, phenylacetate, act as critical side-chain precursors in the industrial fermentation of Penicillin G by the fungus Penicillium chrysogenum. PAA is added to the culture medium, where it is converted into phenylacetyl-CoA and attached to 6-aminopenicillanic acid (6-APA).
Key Aspects of Phenylacetic Acid in Penicillin G Production:
Role as Precursor: PAA is necessary for the biosynthesis of the benzylpenicillin (Penicillin G) side chain.
Industrial Feeding: Because high concentrations of PAA are toxic to P. chrysogenum, it is added in controlled, low amounts to the fermentation medium.
Mechanism: PAA is taken up by the fungus, converted by phenylacetate–CoA ligase (PCL) to phenylacetyl-CoA, and utilized in the final steps of penicillin G synthesis.
Metabolic Pathway: PAA passes through the plasma membrane via passive diffusion of the protonated species.
Other Uses: PAA is also used in the production of drugs like diclofenac, in perfumes, and it is a known precursor for methamphetamine.
Process Details
Optimal Concentrations: Studies indicate that adding PAA at specific concentrations in the growth phase is crucial.
Optimization: Genetic engineering, such as increasing the expression of the phl gene (PAA-CoA ligase), can help the fungus tolerate higher PAA levels and enhance production.
Drawbacks: A portion of the added PAA is oxidized by the fungus, leading to a need for metabolic engineering to rechannel this flux into higher penicillin yields.
Phenylbutyrate (4-PBA) and its active metabolite, phenylacetate, have been investigated in scientific research for their ability to affect the HIV-1 virus, primarily in the context of "shock-and-kill" strategies for HIV latency reversal. While 4-PBA is an FDA-approved drug for urea cycle disorders, its role in HIV research is as an experimental agent designed to force latent (hidden) virus to become active so it can be eliminated.
Key Findings on Phenylbutyrate/Phenylacetate and HIV:
Latency Reversal Agent (LRA): Sodium phenylbutyrate functions as a histone deacetylase (HDAC) inhibitor, which can promote the transcription of HIV-1 from latency in cells.
Mechanism: It works by inhibiting enzymes that pack DNA tightly around histones, thus loosening the chromatin structure and allowing HIV to produce RNA, making the latent cells visible to the immune system.
Preclinical Findings: Studies have shown that 4-PBA can increase HIV-1 expression in latently infected cell lines.
Menin / DOT1L
Epigenetic Proteins
Revumenib (B1, Polyphenol)
Pinometostat (Thiazole)
Menin and DOT1L are critical cofactors in MLL-rearranged (MLL-r) leukemias, where their combined inhibition acts synergistically to trigger leukemia cell differentiation and apoptosis by disrupting the MLL-fusion protein complex on chromatin. Menin inhibitors (revumenib) block Menin-KMT2A binding, while DOT1L inhibitors (pinometostat) target the H3K79 methyltransferase, both suppressing key target genes like HOXA9 and MEIS1.
..
Glutathione S-Transferase
Function: Primarily, GSTs catalyze the conjugation of glutathione (GSH) to harmful, electrophilic substances, rendering them more water-soluble and easier to excrete.
Significance: They function in detoxification, signaling, and protecting cells against oxidative stress-induced cell death.
Structure: They often exist as dimers and are present in almost all aerobic organisms, including plants, where they are crucial for stress response.
Clinical Relevance: Genetic polymorphisms in human GSTs can alter susceptibility to cancer and inflammatory diseases. They are also associated with drug resistance in parasites.
ER-phagy Endoplasmic Reticulum 4-PBA (PBA) 4-Phenylbutyrate
4-Phenylbutyrate (4-PBA) is an FDA-approved chemical chaperone that acts as a potent inhibitor of endoplasmic reticulum (ER) stress, a cellular state linked to neurodegeneration and metabolic diseases. By promoting proper protein folding, 4-PBA reduces protein aggregation, directly counteracting the need for, or assisting in, ER-phagy (selective autophagy of the ER) to manage misfolded proteins.
Key Aspects of 4-PBA in ER Stress Management:
Mechanism of Action: As a chemical chaperone, 4-PBA interacts with exposed hydrophobic segments of unfolded proteins, preventing their aggregation and facilitating correct folding.
ER Stress Reduction: It effectively reduces the accumulation of misfolded proteins in the ER, thereby limiting ER stress-induced apoptosis.
Therapeutic Applications: 4-PBA is utilized to treat urea cycle disorders and has shown promise in treating neurodegenerative diseases (Parkinson’s, Alzheimer's), as well as non-alcoholic fatty liver disease, chronic kidney disease, and ocular HSV-1.
Relationship to ER-phagy: While ER-phagy is a mechanism for removing damaged ER, 4-PBA serves as a protective, upstream agent that reduces the severity of stress, often decreasing the need for massive ER degradation.
4-PBA functions broadly to maintain cellular homeostasis and reduce the pathological impact of ER dysfunction.
Key 4-PBA Derivatives and Related Compounds
C5 (isopropyl 4-PBA): A modified derivative designed to cross the blood-brain barrier.
3-Phenylpropionate (3-PPA): A related short-chain fatty acid tested for chaperone activity.
5-Phenylvaleric acid: A longer-chain derivative studied for ER stress reduction.
6-Phenylhexanoic acid: A further lengthened derivative tested for protein aggregation inhibition
4-Phenylbutyric acid (4-PBA) is a multifunctional small molecule acting as a chemical chaperone to alleviate endoplasmic reticulum (ER) stress, an HDAC inhibitor (HDACi), and an ammonia scavenger used for urea cycle disorders. It stabilizes protein conformation, reduces misfolding, and has potential in treating neurodegenerative and metabolic diseases.
Key Derivatives and Related Compounds:
4-Phenylbutyramide: A derivative often investigated for increased metabolic stability and potency as a chaperone.
3-Phenylpropionic acid (3-PPA): A structurally related, shorter-chain analogue with similar, albeit usually weaker, chemical chaperone properties.
Phenylacetate: The direct metabolite of 4-PBA, which also acts as an ammonia scavenger.
4-phenylbutyrate derivatives: Various synthetic derivatives have been developed to enhance the ability of 4-PBA to prevent protein misfolding, particularly for conditions like ALS.
Key Functions
Chemical Chaperone: Interacts with hydrophobic segments of unfolded proteins to prevent aggregation and reduce ER stress.
HDAC Inhibitor (HDACi): Increases histone acetylation to modulate gene expression, often inhibiting cancer cell proliferation.
Ammonia Scavenger: Metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, which is then excreted in urine, bypassing the urea cycle.
4-PBA is also known for reducing lipotoxicity in hepatoma cells and protecting against cardiac ischemia-reperfusion injury.
Phenylacetic acid (PAA) and its derivative, phenylacetate, act as critical side-chain precursors in the industrial fermentation of Penicillin G by the fungus Penicillium chrysogenum. PAA is added to the culture medium, where it is converted into phenylacetyl-CoA and attached to 6-aminopenicillanic acid (6-APA).
Key Aspects of Phenylacetic Acid in Penicillin G Production:
Role as Precursor: PAA is necessary for the biosynthesis of the benzylpenicillin (Penicillin G) side chain.
Industrial Feeding: Because high concentrations of PAA are toxic to P. chrysogenum, it is added in controlled, low amounts to the fermentation medium.
Mechanism: PAA is taken up by the fungus, converted by phenylacetate–CoA ligase (PCL) to phenylacetyl-CoA, and utilized in the final steps of penicillin G synthesis.
Metabolic Pathway: PAA passes through the plasma membrane via passive diffusion of the protonated species.
Other Uses: PAA is also used in the production of drugs like diclofenac, in perfumes, and it is a known precursor for methamphetamine.
Process Details
Optimal Concentrations: Studies indicate that adding PAA at specific concentrations in the growth phase is crucial.
Optimization: Genetic engineering, such as increasing the expression of the phl gene (PAA-CoA ligase), can help the fungus tolerate higher PAA levels and enhance production.
Drawbacks: A portion of the added PAA is oxidized by the fungus, leading to a need for metabolic engineering to rechannel this flux into higher penicillin yields.
Phenylbutyrate (4-PBA) and its active metabolite, phenylacetate, have been investigated in scientific research for their ability to affect the HIV-1 virus, primarily in the context of "shock-and-kill" strategies for HIV latency reversal. While 4-PBA is an FDA-approved drug for urea cycle disorders, its role in HIV research is as an experimental agent designed to force latent (hidden) virus to become active so it can be eliminated.
Key Findings on Phenylbutyrate/Phenylacetate and HIV:
Latency Reversal Agent (LRA): Sodium phenylbutyrate functions as a histone deacetylase (HDAC) inhibitor, which can promote the transcription of HIV-1 from latency in cells.
Mechanism: It works by inhibiting enzymes that pack DNA tightly around histones, thus loosening the chromatin structure and allowing HIV to produce RNA, making the latent cells visible to the immune system.
Preclinical Findings: Studies have shown that 4-PBA can increase HIV-1 expression in latently infected cell lines.